NCT06350526

Brief Summary

Hematologic malignancies are heterogeneous groups of neoplasia, with frequent pulmonary complications. These complications may be secondary to the patient's comorbidities, to the hemopathy itself, or its treatments. Divided into infectious and non-infectious complications, the etiologies are numerous and varied. This makes the diagnostic approach complex for the clinicians

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
148

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2024

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 1, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

April 5, 2024

Completed
6 months until next milestone

Study Start

First participant enrolled

September 27, 2024

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 21, 2025

Completed
Last Updated

November 24, 2025

Status Verified

November 1, 2025

Enrollment Period

10 months

First QC Date

February 1, 2024

Last Update Submit

November 21, 2025

Conditions

Hematologic Diseases

Outcome Measures

Primary Outcomes (1)

  • Number of patients who had certain radiological patterns associated with pulmonary complications in patients diagnosed with various hematological diseases

    Once through the study

Secondary Outcomes (1)

  • Number of patients who developed complications

    Once through the study

Study Arms (1)

1

patient admitted with hematological disease and pulmonary manifestations

Diagnostic Test: Complete Blood CountDiagnostic Test: C-reactive proteinDiagnostic Test: O2 saturationDiagnostic Test: Serum ferritin and D-dimerDiagnostic Test: Liver and renal function testsDiagnostic Test: Lactate dehydrogenaseDiagnostic Test: coronavirus (SARS-CoV-2) swabRadiation: CT chest

Interventions

Complete Blood CountDIAGNOSTIC_TEST

blood sample

1
C-reactive proteinDIAGNOSTIC_TEST

serum sample

1
O2 saturationDIAGNOSTIC_TEST

blood sample

1
Serum ferritin and D-dimerDIAGNOSTIC_TEST

Blood sample

1
Liver and renal function testsDIAGNOSTIC_TEST

Blood sample

1
Lactate dehydrogenaseDIAGNOSTIC_TEST

Blood sample

1
coronavirus (SARS-CoV-2) swabDIAGNOSTIC_TEST

Throat swab

1
CT chestRADIATION

Radiation

1

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

All patients aged 18 years or older diagnosed with hematological diseases and documented pulmonary manifestations during their disease course will be included in this retrospective study. Data from their medical records will be analyzed by a team of hematologists, pulmonologists, and radiologists.

You may qualify if:

  • All patients aged 18 years or older diagnosed with hematological diseases and documented pulmonary manifestations during their disease course

You may not qualify if:

  • Patients aged under 18 years.
  • Patients without demonstrable evidence of lung involvement.
  • Patients with incomplete medical records or insufficient data to analyze.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut University Hospital

Asyut, Egypt

Location

Related Publications (4)

  • Messe R, Soccal PM, Bergeron A. [Diagnostic approach to pulmonary complications in patients with hematologic malignancy]. Rev Med Suisse. 2021 Nov 17;17(759):1984-1990. French.

    PMID: 34787973BACKGROUND

  • Stecher SS, Lippl S, Stemmler HJ, Schreiber J. [Lung involvement in hematologic systemic diseases]. Internist (Berl). 2018 Sep;59(9):886-897. doi: 10.1007/s00108-018-0471-9. German.

    PMID: 30046891BACKGROUND

  • Maschmeyer G, Carratala J, Buchheidt D, Hamprecht A, Heussel CP, Kahl C, Lorenz J, Neumann S, Rieger C, Ruhnke M, Salwender H, Schmidt-Hieber M, Azoulay E. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Oncol. 2015 Jan;26(1):21-33. doi: 10.1093/annonc/mdu192. Epub 2014 May 15.

    PMID: 24833776BACKGROUND

  • Periselneris J, Brown JS. A clinical approach to respiratory disease in patients with hematological malignancy, with a focus on respiratory infection. Med Mycol. 2019 Jun 1;57(Supplement_3):S318-S327. doi: 10.1093/mmy/myy138.

    PMID: 31292655BACKGROUND

MeSH Terms

Conditions

Hematologic Diseases

Interventions

Blood Cell CountKidney Function Tests

Condition Hierarchy (Ancestors)

Hemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

Cell CountCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisHematologic TestsInvestigative TechniquesCell Physiological PhenomenaBlood Physiological PhenomenaCirculatory and Respiratory Physiological PhenomenaDiagnostic Techniques, Urological

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of Internal Medicine

Study Record Dates

First Submitted

February 1, 2024

First Posted

April 5, 2024

Study Start

September 27, 2024

Primary Completion

August 1, 2025

Study Completion

November 21, 2025

Last Updated

November 24, 2025

Record last verified: 2025-11

Locations

EG(1)